Phathom Pharmaceuticals’ Voquezna Receives the US FDA’s Approval for Relieving Heartburn Associated with Non-Erosive GERD
Shots:
- The US FDA has approved Voquezna 10mg tablets to relieve heartburn linked to non-erosive gastroesophageal reflux disease (Non-Erosive GERD)
- Approval was based on the P-III (PHALCON-NERD-301) trial assessing the safety & efficacy of Voquezna (10mg & 20mg, QD) vs PBO to relieve heartburn in adults (n=776) with Non-Erosive GERD for over 4wks., with a 20wk. extension for long-term treatment
- Study showed mean percentage of heartburn-free days was 45% vs 28% & median percentage of 24-hour heartburn-free days was 48% vs 17% after wk.4, with improvements in percentages of heartburn-free days & nights plus days without rescue antacid use. Data was highlighted at DDW 2024 & published in Clinical Gastroenterology and Hepatology
Ref:Phathom Pharmaceuticals | Image: Phathom Pharmaceuticals
Related News:- Phathom Reports P-III Study (PHALCON-NERD-301) Results of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
